Indago Research and Health Center | Hialeah, FL

Research site

(Unclaimed)

Location

3700 West 12th Avenue Suite 300, Hialeah, Florida, United States of America

Site insights

Top conditions

Top treatments

BI 685509

Lorundrostat

BMS-986165

Flurpiridaz

Maridebart Cafraglutide

K-877

Triglyceride

SAR440340

Dapagliflozin

18F

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 46 total trials

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting

Cytomegalovirus Infection

Biological: mRNA-1647

Biological: Placebo

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adu...

Active, not recruiting

Respiratory Syncytial Virus

Biological: mRNA-1345

Comparative Efficacy, Safety, PK, and Immunogenicity Study

this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy,...

Active, not recruiting

Osteoporosis, Postmenopausal

Biological: Denosumab

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria

This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and...

Active, not recruiting

Chronic Kidney Disease

Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD

Drug: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling

Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Drug: Maridebart cafraglutide

Drug: Placebo

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1)

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling

Obesity

Drug: Placebo

Drug: Maridebart Cafraglutide

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting

Psoriasis

Drug: BMS-986165

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypert...

Active, not recruiting

Hypertension

Drug: lorundrostat

Drug: Placebo

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Itepekimab SAR440340

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling

Alzheimer Disease, Early Onset

Other: Placebo

Drug: BMS-986446